EA201892625A1 - КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ - Google Patents
КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИInfo
- Publication number
- EA201892625A1 EA201892625A1 EA201892625A EA201892625A EA201892625A1 EA 201892625 A1 EA201892625 A1 EA 201892625A1 EA 201892625 A EA201892625 A EA 201892625A EA 201892625 A EA201892625 A EA 201892625A EA 201892625 A1 EA201892625 A1 EA 201892625A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- acc
- alcoholic
- carboxylase
- coa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В настоящем изобретении предложены способы лечения, стабилизации, или снижения тяжести, или замедления прогрессирования неалкогольной жировой болезни печени с применением ингибитора ACC отдельно или с одним или более дополнительными терапевтическими агентами.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101726P | 2015-01-09 | 2015-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892625A1 true EA201892625A1 (ru) | 2019-07-31 |
Family
ID=56356482
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892625A EA201892625A1 (ru) | 2015-01-09 | 2016-01-08 | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ |
EA201791258A EA201791258A1 (ru) | 2015-01-09 | 2016-01-08 | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791258A EA201791258A1 (ru) | 2015-01-09 | 2016-01-08 | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
Country Status (13)
Country | Link |
---|---|
US (2) | US20180021341A1 (ru) |
EP (2) | EP3242722A4 (ru) |
JP (2) | JP2018501276A (ru) |
KR (1) | KR20170102299A (ru) |
CN (1) | CN107106873A (ru) |
AU (1) | AU2016205138A1 (ru) |
BR (1) | BR112017014341A2 (ru) |
CA (1) | CA2972919A1 (ru) |
EA (2) | EA201892625A1 (ru) |
HK (2) | HK1243369A1 (ru) |
MX (1) | MX2017008844A (ru) |
SG (1) | SG11201705361PA (ru) |
WO (1) | WO2016112305A1 (ru) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
NZ738525A (en) | 2015-07-06 | 2019-03-29 | Gilead Sciences Inc | Cot modulators and methods of use thereof |
HUE053175T2 (hu) | 2015-11-25 | 2021-06-28 | Gilead Apollo Llc | ACC-gátló észterek és azok alkalmazása |
EP3380480B1 (en) * | 2015-11-25 | 2022-12-14 | Gilead Apollo, LLC | Pyrazole acc inhibitors and uses thereof |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
CN117229994A (zh) | 2016-11-04 | 2023-12-15 | 儿童医院医学中心 | 肝类器官疾病模型以及其制备和使用方法 |
US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
MX2019005533A (es) * | 2016-11-10 | 2020-02-07 | Galmed Res And Development Ltd | Tratamiento de la fibrosis. |
KR20190083660A (ko) * | 2016-11-10 | 2019-07-12 | 갈메드 리서치 앤드 디벨롭먼트 리미티드 | 비-알코올성 지방 간질환 환자에 있어서 섬유증의 억제 |
SG10202105768WA (en) | 2016-12-05 | 2021-06-29 | Childrens Hospital Med Ct | Colonic organoids and methods of making and using same |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN108341830B (zh) * | 2017-01-22 | 2021-03-02 | 广东东阳光药业有限公司 | 噻吩并嘧啶衍生物及其在药物中的应用 |
US11142531B2 (en) | 2017-03-24 | 2021-10-12 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof |
CA3056925A1 (en) * | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
ES2927019T3 (es) * | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
EP3609496A1 (en) * | 2017-04-12 | 2020-02-19 | Gilead Sciences, Inc. | Methods of treating liver disease |
EP3612175A1 (en) * | 2017-04-18 | 2020-02-26 | Genfit | Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent |
EP3609523B1 (en) * | 2017-04-24 | 2022-03-02 | Tsinghua University | Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy |
WO2018236896A1 (en) * | 2017-06-19 | 2018-12-27 | Arena Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR THE TREATMENT OF NAFLD AND NASH |
EP3655409B1 (en) | 2017-07-17 | 2023-12-27 | Nanjing Ruijie Pharmatech Co., Ltd. | Novel compounds and their uses as acc inhibitors |
US11186587B2 (en) * | 2017-07-26 | 2021-11-30 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Compound as ACC inhibitor and use thereof |
CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
CN111406051A (zh) | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环 |
US11033601B2 (en) * | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
TWI814744B (zh) * | 2017-10-06 | 2023-09-11 | 美商基利科學股份有限公司 | 包含acc抑制劑之組合療法 |
CN114920818B (zh) * | 2017-11-06 | 2024-02-27 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
CN107693514A (zh) * | 2017-12-04 | 2018-02-16 | 威海贯标信息科技有限公司 | 一种鲁格列净组合物 |
CN111788195B (zh) | 2018-01-31 | 2023-11-21 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂 |
US20210113561A1 (en) * | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2019209738A1 (en) * | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CA3104246A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2020037023A1 (en) * | 2018-08-14 | 2020-02-20 | Avolynt | Method for treating primary sclerosing cholangitis |
KR102614808B1 (ko) | 2018-08-31 | 2023-12-19 | 화이자 인코포레이티드 | Nash/nafld 및 관련 질환의 치료를 위한 조합물 |
KR20210057758A (ko) * | 2018-09-06 | 2021-05-21 | 갈메드 리서치 앤드 디벨롭먼트 리미티드 | 간 질환을 치료하기 위한 병용 요법 |
CN110950884B (zh) * | 2018-09-27 | 2024-03-26 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
JP2022513101A (ja) * | 2018-11-20 | 2022-02-07 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | スピロ環系化合物及びその医薬用途 |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
WO2020208205A1 (en) * | 2019-04-10 | 2020-10-15 | Genfit | Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists |
JP2022532706A (ja) | 2019-05-08 | 2022-07-19 | アリゴス セラピューティクス,インコーポレーテッド | THR-βの調節物質およびその使用方法 |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
EP3995498A4 (en) | 2019-07-02 | 2023-03-01 | Sunshine Lake Pharma Co., Ltd. | THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE |
WO2021018820A1 (en) | 2019-07-29 | 2021-02-04 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
CN110628810B (zh) * | 2019-08-13 | 2022-06-28 | 浙江大学 | 一种提高植物光合效率的方法 |
KR20210027169A (ko) * | 2019-08-30 | 2021-03-10 | (주)셀트리온 | 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물 |
US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
EP4090659B1 (en) | 2020-01-15 | 2024-06-12 | HepaRegeniX GmbH | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
CN115335055A (zh) * | 2020-03-11 | 2022-11-11 | 东亚St株式会社 | 用于预防或治疗非酒精性脂肪性肝炎的药物组合物 |
AU2021249010A1 (en) | 2020-03-30 | 2022-10-06 | Gilead Sciences, Inc. | Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
AU2021245924B2 (en) | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
CN111407892A (zh) * | 2020-04-08 | 2020-07-14 | 中国药科大学 | Acsl4及其在nash中的应用 |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
JPWO2021235508A1 (ru) * | 2020-05-21 | 2021-11-25 | ||
EP4000616A1 (en) | 2020-11-17 | 2022-05-25 | Inventiva | Combination therapy for the treatment of a liver disease |
WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
US20230079863A1 (en) | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療fxr誘發之搔癢之il-31調節劑 |
WO2023034381A1 (en) * | 2021-08-31 | 2023-03-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Quantitative systems pharmacology methods for identifying therapeutics for disease states |
WO2023047203A1 (en) * | 2021-09-25 | 2023-03-30 | Torrent Pharmaceuticals Ltd | Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent |
WO2023090411A1 (ja) | 2021-11-19 | 2023-05-25 | 塩野義製薬株式会社 | 心疾患または骨格筋の疾患の治療用医薬 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110288114A1 (en) * | 2008-06-20 | 2011-11-24 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
US20100113473A1 (en) * | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
WO2012090219A2 (en) * | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
SI2776038T1 (en) * | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
EP2994141A4 (en) * | 2013-05-10 | 2016-11-23 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
CA2911818A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
JP6417401B2 (ja) * | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
AU2014262638A1 (en) * | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
-
2016
- 2016-01-08 CA CA2972919A patent/CA2972919A1/en not_active Abandoned
- 2016-01-08 EA EA201892625A patent/EA201892625A1/ru unknown
- 2016-01-08 CN CN201680004801.2A patent/CN107106873A/zh active Pending
- 2016-01-08 EP EP16735485.1A patent/EP3242722A4/en not_active Withdrawn
- 2016-01-08 JP JP2017535411A patent/JP2018501276A/ja not_active Withdrawn
- 2016-01-08 EA EA201791258A patent/EA201791258A1/ru unknown
- 2016-01-08 US US15/541,008 patent/US20180021341A1/en not_active Abandoned
- 2016-01-08 MX MX2017008844A patent/MX2017008844A/es unknown
- 2016-01-08 SG SG11201705361PA patent/SG11201705361PA/en unknown
- 2016-01-08 AU AU2016205138A patent/AU2016205138A1/en not_active Abandoned
- 2016-01-08 KR KR1020177021086A patent/KR20170102299A/ko unknown
- 2016-01-08 WO PCT/US2016/012673 patent/WO2016112305A1/en active Application Filing
- 2016-01-08 EP EP19176040.4A patent/EP3597271A1/en not_active Withdrawn
- 2016-01-08 BR BR112017014341-0A patent/BR112017014341A2/pt not_active Application Discontinuation
-
2018
- 2018-02-28 HK HK18102859.6A patent/HK1243369A1/zh unknown
- 2018-05-04 HK HK18105783.0A patent/HK1246232A1/zh unknown
-
2019
- 2019-05-13 US US16/410,894 patent/US20190381045A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020072689A patent/JP2020109130A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2972919A1 (en) | 2016-07-14 |
EA201791258A1 (ru) | 2017-12-29 |
JP2020109130A (ja) | 2020-07-16 |
EP3242722A1 (en) | 2017-11-15 |
CN107106873A (zh) | 2017-08-29 |
US20180021341A1 (en) | 2018-01-25 |
KR20170102299A (ko) | 2017-09-08 |
EP3242722A4 (en) | 2018-07-11 |
BR112017014341A2 (pt) | 2018-03-27 |
JP2018501276A (ja) | 2018-01-18 |
US20190381045A1 (en) | 2019-12-19 |
HK1246232A1 (zh) | 2018-09-07 |
SG11201705361PA (en) | 2017-08-30 |
AU2016205138A1 (en) | 2017-07-13 |
HK1243369A1 (zh) | 2018-07-13 |
MX2017008844A (es) | 2018-03-14 |
WO2016112305A1 (en) | 2016-07-14 |
EP3597271A1 (en) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892625A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ | |
CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
BR112019003914A2 (pt) | inibidores de processos metabólicos celulares | |
CL2017002567A1 (es) | Composiciones para modular la expresión de c9orf72 | |
EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
UY36357A (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) | |
BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
PH12017501879A1 (en) | Methods for treating cancer | |
MX2022012386A (es) | Compuestos inhibidores de metaloenzimas. | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
EA201991360A1 (ru) | Модифицированные олигонуклеотиды для лечения поликистозной болезни почек | |
NZ740817A (en) | Pcna inhibitors | |
CL2018002074A1 (es) | Composiciones y métodos para tratar infecciones. | |
CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
EA201792288A1 (ru) | Способы лечения рака | |
EA201691896A1 (ru) | Соединения и способы их применения |